Latest Articles

Publication Date
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance HIT Consultant

Published: Feb. 18, 2026, 5:03 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva - PharmiWeb.com

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Priva PharmiWeb.com

Published: Feb. 18, 2026, 4:05 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - PharmiWeb.com

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement PharmiWeb.com

Published: Feb. 18, 2026, 4:05 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - The AI Journal

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement The AI Journal

Published: Feb. 18, 2026, 1:25 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement Business Wire

Published: Feb. 18, 2026, 1 p.m.
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Karyopharm Therapeutics Inc. SEC 10-K Report TradingView

Published: Feb. 13, 2026, 11:05 a.m.
Glycomic Insights in Gynecological Disease: From Molecular Mechanisms to Precision Diagnostics and Therapeutics.

Gynecological diseases-encompassing polycystic ovary syndrome, endometriosis, infertility, and malignancies-represent a significant global health burden affecting women's quality of life, reproductive capacity, and long-term health outcomes. While traditional diagnostics rely on …

Published: Feb. 3, 2026, midnight
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan The Manila Times

Published: Jan. 29, 2026, 1:43 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!